Baxter(US:BAX) Markets.Businessinsider.Com·2025-11-02 13:28Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the Novum LVP device, which has been linked to serious patient risks and malfunctions [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 in Baxter between February 23, 2022, and July 30, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Baxter, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [2][7]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions and posed risks of serious injury or death to patients [5]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to a heightened risk of product withdrawal from the market [5]. Group 3: Stock Impact - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [6].